Sign in

    Andrew Fein

    Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co.

    Andrew Fein is a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co., specializing in the biotechnology and life sciences sectors. He covers companies such as Annexon Inc., DBV Technologies, Syros Pharmaceuticals, Vertex Pharmaceuticals, and Savara among others, and maintains a performance track record that includes a 45.97% success rate and an average return of 8.68% across over 600 equity ratings, as well as recognition with Institutional Investor poll honorable mentions. Fein began his career at J.P. Morgan H&Q, held senior roles at firms including Leerink Swann, Jefferies, Piper Jaffray, Collins Stewart, and Chardan Capital Markets, before joining H.C. Wainwright as Managing Director in May 2013. He holds a Bachelor of Arts degree from Yale University and is registered with FINRA in his capacity as a research analyst.

    Andrew Fein's questions to Wave Life Sciences (WVE) leadership

    Andrew Fein's questions to Wave Life Sciences (WVE) leadership • Q2 2025

    Question

    Andrew Fein of H.C. Wainwright & Co. asked for takeaways from competitor data at the ADA conference and how it informs the WVE-007 strategy. For WVE-006, he relayed KOL feedback suggesting the importance of reaching ~22 micromolar of AAT and replicating an acute phase response.

    Answer

    President & CEO Paul Bolno responded that competitor data reinforces the importance of muscle preservation, an area where WVE-007 is designed to excel as a monotherapy. For WVE-006, he agreed with the KOLs, stating that RNA editing is designed to preserve the body's natural ability to mount an acute phase response, a key differentiator from protein replacement therapy. He noted this was a core part of the original thesis for using RNA editing in AATD.

    Ask Fintool Equity Research AI